High-grade gliomas harbor abundant myeloid cells that suppress anti-tumor immunity and support tumor growth. Targeting transcription factors, such as NF-κB p50, that mediate suppressive myeloid M2 polarization may prove therapeutic. GL261-Luc glioblastoma cells were inoculated into wild-type and p50 −/− mice, followed by analysis of tumor growth, survival, tumor myeloid cells, and T cells. The absence of host p50 slows tumor growth and enables regression in 30% of recipients, leading to prolonged survival. Tumors developing in p50 −/− mice possess a greater concentration of tumor-infiltrating myeloid cells (TIMs) than those in wild-type mice. TIMs are predominantly F4/80 hi macrophages which, along with tumor-associated microglia, express increased pro-inflammatory M1 and reduced immune-suppressive M2 markers. In p50 −/− mice, total tumor CD4 T cells are threefold more abundant, whereas CD8 T-cell numbers are unchanged, and both produce increased IFNγ and Granzyme B. Naïve splenic p50 −/− CD8 T cells manifest increased activation, whereas naïve p50 −/− and WT CD4 T cells show similar Th1, Th2, and Th17 polarization. Antibody targeting CD4, but not CD8, fully obviates the p50 −/− survival advantage. Combined CD4 and CD8 T-cell depletion reverses myeloid M2 polarization in wild-type hosts, without affecting myeloid M1 polarization in p50 −/− hosts. Finally, gliomas grow similarly in p50(f/f) and p50(f/f);Lysozyme-Cre mice, the latter having reduced p50 specifically in myeloid cells and tumor microglia. Thus, high-grade glioma T cells play a key role in directing M2 polarization of tumor myeloid cells, and reducing NF-κB p50 in both tumor myeloid cells and T cells may contribute to glioma therapy.
Introduction
Glioblastoma (GBM) is a uniformly fatal brain tumor. The microenvironment of high-grade gliomas contains an abundance of myeloid cells, which comprise as much as 40% of the tumor [1, 2] . Glioma myeloid cells broadly fall into two categories: (1) brain-resident microglia, which derive from embryonic macrophages and are present in the healthy brain and (2) tumor-infiltrating myeloid cells (TIM) that are derived from blood monocytes and granulocytes and are recruited to the brain under pathological conditions [3, 4] .
Blood monocytes can mature into tumor-associated macrophages (TAMs); in addition, TIM can retain a more immature phenotype and be classified further into granulocytic or monocytic MDSC [5] [6] [7] [8] [9] . Gliomas produce cytokines such as CSF1 that polarize TAMs and microglia towards the immune-suppressive, tumor-supportive M2, as opposed to the pro-inflammatory M1 phenotype [1, 10] . M2 TAM also support tumor growth by producing proangiogenic, proliferative, and invasive factors.
Due to their abundance and ability to influence T-cell function, glioma myeloid cells represent a potential therapeutic target. Supporting the utility of tumor myeloid reprogramming, inhibiting the tyrosine kinase activity of the CSF1 receptor alters TAM in a PDGF;Cdkn2a −/− murine glioma model by reducing M2 and increasing M1 markers, leading to prolonged survival. The same agent slows growth of human GBM in NOD/SCID mice [11] . However, gliomas secrete additional cytokines capable of inducing M2 polarization, including GM-CSF and IL-4, ultimately enabling outgrowth of CSF1R inhibitor-resistant gliomas [12, 13] .
CSF1, GM-CSF, and IL-4 signaling may converge on common transcription factors to favor M2 gene expression. Transcription factors contributing to M2 macrophage polarization include NF-κB p50 (p50), C/EBPβ, KLF4, STAT6, PPARγ, and RORC1 [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Melanoma and fibrosarcoma cells grow more slowly in p50 −/− compared with wildtype (WT) hosts, and also in WT hosts transplanted with p50 −/− compared with WT marrow [15] , but detailed characterization of the cellular mechanisms responsible for slowed tumor growth is lacking. We add to the existing literature by investigating the contribution of host p50 to the growth of glioma, a tumor that arises in a unique microenvironment. We find that intracranial GL261 glioma cells grow more slowly in p50 −/− mice and exhibit striking tumor regression in a subset of these mice, with prolonged survival. We have characterized changes in the glioma immune microenvironment associated with this dramatic phenotype and demonstrate not only macrophage and microglia reprogramming, but also a previously unappreciated role for T cells in directing this process. In addition, we show that glioma growth is unimpaired in a novel mouse model lacking p50 specifically in macrophages, activated monocytes, and granulocytes. We conclude that targeting NF-κB p50 in T cells, or in both T cells and myeloid cells, may provide an effective glioma immunotherapy.
Materials and methods

Tumor inoculation, imaging, and survival analysis
GL261-Luc cells [24] were grown in DMEM with 10% FBS. They were inoculated intra-cranially into the striatum as described [25] . For tumor imaging, mice were injected with luciferin (100 μg/g i.p.) in PBS; after 10 min the mice were anesthetized using isofluorane-O 2 gas and imaged using the Spectrum (Perkin Elmer) in vivo imaging system (IVIS). To deplete CD4 or CD8 T cells, WT and p50 −/− mice were administered rat-anti-CD4 or CD8 antibodies (Bio-X-Cell) i.p.
Tumor myeloid and T-cell isolation
Mice anesthetized with ketamine and xylazine were perfused with ice-cold PBS at 7 mL/min for 8 min via their exposed left ventricle using a syringe pump. Brains were removed from euthanized mice and placed in calcium/magnesiumfree HBSS. Enzymatic cell dissociation was accomplished using Neural Tissue Dissociation Kit P (Miltenyi), following the protocol for the Octo Dissociator, program 37C_ABDK. HBSS with 1.26 mM CaCl 2 , 0.5 mM MgCl 2 , and 0.4 mM MgSO 4 was then added, followed by passage through a 40 μm cell strainer and centrifugation at 300×g for 5 min. The pellet was resuspended in 7 mL 30% isotonic Percoll in PBS and centrifuged at room temperature for 10 min at 700×g. The top myelin layer and Percoll were aspirated, and the cell pellet was washed with MACS buffer (Miltenyi). Cells were then either stained for flow cytometry (FC), or separated into CD11b + and CD11b − or CD3 + and CD3 − cell fractions using CD11b or CD3 positive selection kits and LS columns (Miltenyi).
Tumor myeloid and T-cell subset and activation analyses
All antibody staining was preceded by 15 min of 1:50 FcγR block in FC buffer, on ice. Extracellular antibodies were then added to FC buffer containing FcγR block, and incubated for 45 min on ice. Intracellular staining was accomplished after surface staining using the Foxp3 staining kit (eBioscience). Myeloid subsets were stained with anti-CD11b-FITC, anti-Ly6C-AF700, anti-MR-PE-Cy7, anti-CD11c-PE/ Dazzle594, anti-Ly6G-BV605 (BioLegend), anti-MHCIIeFluor450 (eBioscience), and anti-F4/80-APC (BioRad). To evaluate Tregs, cells were stained with anti-CD3-AF488, anti-CD4-APC, anti-CD25-PerCP-Cy5.5 (BioLegend), and anti-Foxp3-PE (BD Pharmingen). To assess T-cell activation, total tumor cells were incubated for 4 h at 37 °C in a 5% CO 2 incubator with Protein Transport Inhibitor Cocktail containing brefeldin A and monensin, or with Cell Stimulation Cocktail containing protein transport inhibitors and PMA/ionomycin (eBioscience). Cells were then stained with anti-CD3-AF488, anti-CD4-PE, and anti-CD8-PerCP-Cy5.5 followed by intracellular stain with anti-IFNγ-APC (BioLegend). In addition, 1E5 CD3 + cells were stimulated with 4E4 CD3/CD28 Dynabeads (ThermoFisher) for 3 days, followed by staining using anti-CD3-PerCP-Cy5.5, anti-CD8-BV650, anti-CD4-BV605, anti-IFNγ-APC, anti-TNFα-BV421 (BioLegend), and anti-GranzymeB-PE (eBioscience).
Naïve splenic T-cell analysis
To obtain naïve CD4 T cells, spleens were passed through a cell strainer, subjected to red cell lysis, and selected using a CD8 positive selection kit (Miltenyi). CD8 − cells were then subjected to negative selection using a naïve CD4 T-cell isolation kit (Miltenyi). The cells bound to the column included APC. To obtain naïve CD8 T cells, splenocytes were subjected to selection using the Pan T-cell isolation kit II (Miltenyi), yielding CD3 + T cells and the bound CD3 − fraction that includes APCs. The CD3 + cells were then further processed using a naïve CD8α T-cell isolation kit (Miltenyi). Naïve T cells were combined with irradiated (3000 cGy) APCs and cultured with different cytokine and antibody combinations to favor lineage polarization, plus anti-CD3 antibody, followed by PMA/ionomycin stimulation and FC analysis [26] .
Bone-marrow-derived myeloid cells and peritoneal macrophages
To obtain bone-marrow-derived macrophages (BMDM), marrow was cultured on bacterial dishes with DMEM, 10% heat-inactivated FBS, and CSF1 (20 ng/ml) for 7 days, followed by stimulation of adherent cells with IL-4 (20 ng/ml) or IFNγ (20 ng/ml) or vehicle for 24 h. To isolate peritoneal macrophages, 10 ml of ice-cold HBSS was inserted into the peritoneal cavity and removed. Cells were resuspended in DMEM with 10% heat-inactivated FBS and transferred to a tissue culture plate overnight.
RNA, DNA, and western blot analyses
RNA was isolated using NucleoSpin RNA II (MacheryNagel). First-strand cDNA was prepared using AMV reverse transcriptase (Promega) and oligodT. Quantitative realtime PCR (qRT-PCR) was carried out using Lo-Rox SYBR Green (Alkali Scientific). Primers are listed (Supplementary  Table S1 ). Genomic DNA from p50(f/f) and p50(f/f);LysCre BMDM was PCR amplified using intron 3 primer 5′-CAC AAG TGT GTG GAG GCT GAAGG-3′ and intron 4 primer 5′-ACT TTC CTA CTG TTT CCC CAG AGC C-3′, followed by agarose gel electrophoresis and ethidium bromide staining. Total cellular proteins prepared in Laemmli sample buffer were subjected to Western blotting using p50 (13586, Cell Signaling) and β-actin (AC-15, Sigma) antibodies.
Data analysis
Survival curves were compared using the log rank test. Tumor bioluminescence, myeloid and T-cell subsets, and RNA expression values were compared using the Student t test. Means and SEs are shown.
Results
Absence of NF-κB p50 slows GL261 glioma growth and prolongs survival GL261 cells, derived from a B6 mouse by chemical mutagenesis, are widely used as a glioma model. These cells closely mimic human GBM angiogenesis and invasiveness and contain abundant M2 TAMs [24] . WT or p50 −/− mice were implanted with GL261-Luc cells and assessed weekly by IVIS to track tumor growth. Representative images for WT and p50 −/− recipients are shown (Fig. 1a , left). We found that 12 of the 39 tumors in p50 −/− hosts that were detectable on day 14 subsequently regressed, as illustrated by the second p50 −/− mouse. In contrast, only 1 of 43 such tumors in WT mice regressed (Fig. 1a, right) . p50 −/− tumor recipients had significantly prolonged survival compared with WT recipients (Fig. 1b) , with a trend toward reduced tumor size on day 14 and a significant, > threefold reduction in tumor size on day 21 (Fig. 1c) . The day 21 data underestimates the difference in tumor sizes, as 11 WT recipients died prior to day 21 imaging.
Characterization of glioma-associated myeloid cells
Previous studies demonstrate that tumors harb o r F 4 / 8 0 h i Ly 6 C in t/ lo M H C I I h i/l o m a c ro p h a ge s , F4/80 lo Ly6C hi MHCII lo monocytes, and Ly6G + granulocytes, the latter two subsets potentially representing monocytic or granulocytic MDSCs [27] [28] [29] . We sought to characterize GL261 glioma-associated myeloid cells. CD11b is a pan-myeloid marker. Microglia can be partially resolved from other myeloid populations by their low/intermediate expression of CD45 [27, 30] . FC demonstrates abundant CD45 int CD11b int microglia in healthy tumor-free brains, but very few CD45
hi CD11b hi cells (less than 0.5% of total cells and 8% of CD45 + cells, on average, n = 3, not shown). In WT and p50 −/− tumor-bearing mice, we observe a large increase in CD45 hi CD11b hi cells, which we denote tumor-infiltrating myeloid cells or TIMs (Fig. 2a, left) . TIMs comprise about 40%, and microglia 45%, of CD45 + cells in both WT and p50 −/− tumor-bearing brains ( (Fig. 2c ). Ly6C and MHCII staining has previously been used to subdivide TIM subsets, with Ly6C int MHCII hi cells correlating with reduced tumor growth [28, 29, 31] . As we perfused mice with PBS prior to brain isolation, we detect few tumorassociated Ly6C hi monocytes (Supplementary Fig. 1a ), but do find Ly6C int and Ly6C lo cells with varying expression of MHCII, as seen in a representative FC plot (Fig. 2d, left) ; these uniformly express the F4/80 macrophage marker (Supplementary Fig. 1b) (Fig. 2d, right) . When normalized to tumor size using bioluminescence, we observe a fourfold increase in the density of Ly6C int MHCII hi TIMs, and no change in the density of Ly6C lo MHCII hi TIMs, in p50 −/− mice (not shown). In a rat glioma model, CD11c hi macrophages potentiated orthotopic tumor growth [32] . Consistent with reduced tumor growth, CD11c expression was decreased in the predominant Ly6C int MHCII hi TIM subset, but was unchanged in the other three Ly6C;MHCII populations in p50 −/− hosts (Fig. 2e) .
Absence of NF-κB p50 favors a pro-inflammatory M1 TIM phenotype
The frequency of TIMs expressing MHCII was increased and of those expressing the M2 marker mannose receptor (MR) decreased in p50 −/− compared with WT tumor recipients (Fig. 3a, left) . The density of MHCII hi TIMs and MR − TIMs were both increased in p50 −/− mice (Fig. 3a,  right) . We further found that MR expression was decreased in all four p50 −/− TIM Ly6C;MHCII subsets (Fig. 3b) . Fig. 2a ). The proportion of WT vs p50 −/− microglia expressing MHCII was increased (27 vs 56%, p = 0.001) and the proportion expressing MR decreased (14 vs 11%, p = 0.05); and only 3% of WT or p50 −/− microglia expressed CD11c ( Supplementary Fig. 2b ).
To evaluate additional polarization markers, we isolated tumor CD11b + cells 14-16 days after GL261-Luc inoculation and evaluated RNA from these cells by qRT-PCR (Fig. 3c) Fig. 3 ). Increased tumor T-cell activation in glioma-bearing NF-κB p50 −/− mice Glioma-bearing WT and p50 −/− brains were analyzed by FC for total CD4 and CD8 tumor-infiltrating lymphocytes (TIL) (Fig. 4a, left) . CD4 TIL were increased ~ threefold in tumors forming in p50 −/− mice, both in absolute number and density. CD8 TIL numbers were not significantly changed (Fig. 4a, right) . CD4 TIL were the predominant tumor T cell present, being ~ twofold greater than CD8 TIL in WT mice, and ~ threefold greater than CD8 TIL in p50 −/− mice. Of note, in the absence of tumor there were only 10,400 CD4 and 450 CD8 T cells per brain, on average (n = 3, not shown). CD25 + Foxp3 + Tregs were reduced ~ 1.5-fold, as a percent of total CD4 TIL, in p50 −/− recipients (Fig. 4b) ; however, due to the overall increase in the total number 
RNAs prepared from tumor CD11b
+ cells on day 14 after GL261-Luc inoculation were subjected to qRT-PCR analysis for indicated M1 and M2 markers. The relative expression of each mRNA, normalized to cyclophilin A, is shown for WT or p50 −/− recipients, with expression in WT mice set to 1.0. Mean and SE are shown for 16 mice total in each group, combined from three separate experiments. *p < 0.05, **p < 0.01, ***p < 0.001 of CD4 TIL in p50 −/− mice, total numbers of Tregs were unchanged and Treg density was increased in the absence of p50 (Supplementary Fig. 4a ).
Intracellular IFNγ expression, a marker of T-cell activation, was assessed in TIL after 4 h exposure to PMA/ionomycin or vehicle (Fig. 4c) . In p50 −/− mice, IFNγ expression was increased in vehicle-treated CD4 and CD8 TIL, as well as in stimulated CD4 TIL. Notably, the density of vehicle-treated IFNγ-expressing CD4 TIL was 10-fold higher than that of CD8 TIL in p50 −/− recipients, and ~ threefold greater in absolute number. Designating IFNγ-expressing T cells as T effectors, the p50 −/− Treg:CD4 effector ratio was reduced 10-fold in vehicle-treated and threefold in PMA/ionomycin-treated cells as compared to WT ratios. The p50 −/− Treg:CD8 effector ratio was reduced twofold in vehicle-treated cells and was slightly increased in PMA/ionomycin-treated cells (Supplementary Fig. 4b ). Intracellular IFNγ Granzyme B, and TNFα expression were also assessed in TIL after 3 days of ex vivo stimulation with CD3/CD28 antibodies (Fig. 4d) . p50 −/− CD4 −/− CD8 TIL also had increased Granzyme B. Thus, compared with WT mice, tumors from p50 −/− mice possess elevated numbers of CD4 TIL that exhibit a more activated, anti-tumor phenotype at baseline and upon stimulation. CD8 TIL are also more activated in p50 −/− mice at baseline, albeit at lower numbers.
To evaluate the cell-intrinsic impact of p50 deletion in T cells, we isolated naïve splenic CD4 T cells or CD8 T cells from WT and p50 −/− mice and cultured them under conditions that favor differentiation into several CD4 subsets or the CD8 Tc1 subset. Evaluation of intracellular IFNγ, Foxp3, and IL-17 expression indicated that p50 −/− CD4 T cells possess no defect in their ability to become Th1, Treg, or Th17 cells. IL-4 secretion was unchanged in p50 −/− CD4 T cells differentiated into the Th2 subset ( Supplementary  Fig. 5a ). In contrast, CD8 Tc1 formation was increased in the absence of p50, indicated by elevated proportions of CD8 T cells expressing IFNγ, Granzyme B, and TNFα (Supplementary 
T-cell depletion eliminates the survival benefit of p50 −/− and reverses M2 polarization in WT hosts
To remove T cells, mice received three doses of CD4 or CD8 antibody 7, 5, and 3 days prior to GL261-Luc implantation; depletion was confirmed by analysis of peripheral blood 1 day prior to implantation ( Fig. 5a ). CD4 antibody fully obviated the survival advantage of p50 −/− mice, whereas CD8 antibody reduced, but did not eliminate, this advantage (Fig. 5b) . CD8 T cells recovered to 3% of peripheral blood cells by day 19, on average, compared to 18% at baseline (not shown), potentially reducing the effect of CD8 depletion on survival. Neither CD4 nor CD8 antibody affected the survival of WT mice (Supplementary Fig. 6 ).
To evaluate TIM polarization in the absence of T cells, we pre-depleted CD4 and CD8 cells, inoculated mice with GL261-Luc, and then isolated brain CD11b + cells on day 14. We evaluated M1 and M2 markers by qRT-PCR, focusing on those markers that differed without depletion (Fig. 5c) . Strikingly, T-cell depletion in WT mice increased IL-12 and TNF (M1) and decreased MR, Mmp9, Ccl17, Ccl22, and Arg (M2) to levels seen in untreated p50 −/− mice. In contrast, T-cell depletion of p50 −/− mice had little effect on these mRNAs, with the exception of Arg. T-cell depletion did not increase the expression of IL-1 or Nos2 in WT mice. The lack of prolonged survival in WT mice depleted of CD4 or CD8 T cells suggests that the resulting M2-to-M1 shift in TIM is not as strong as that resulting from p50 gene deletion.
Deletion of neutrophil/macrophage NF-κB p50 does not slow glioma growth p50(f lacZ /+) mice, harboring a floxed p50 exon 4 with an intron 3 lacZ cassette flanked by frt sites, were bred with ROSA26-FLPo and then Lysozyme-Cre to generate p50(f/f) and p50(f/f);Lys-Cre mice. Lys-Cre deletes floxed alleles in activated monocytes, macrophages, and granulocytes [33] . Efficient Lys-Cre-mediated deletion of exon 4 was evident upon PCR of BMDM genomic DNA (Fig. 6a,  left) , resulting in markedly reduced p50 RNA and protein in BMDM at baseline and after stimulation with IL-4 or IFNγ (Fig. 6a, center and right) . The p105 precursor of p50 was also reduced. Efficient deletion was also evident in peritoneal macrophages (Fig. 6b) . Survival of p50(f/f) or p50(f/f);Lys-Cre mice inoculated with GL261-Luc glioma cells was essentially identical, with tumor growth also unaffected by reduced myeloid p50 (Fig. 6c) . Analysis of tumor CD11b
+ cell RNA reveals a trend towards increased Nos2 and TNF (M1), as well as reduced Ccl17 with a trend towards reduced Ccl22 (M2); in contrast to p50 −/− tumor hosts, Fizz1, MR, Mmp9, and Arg (M2) were not reduced in p50(f/f);Lys-Cre mice (Fig. 6d) . Lack of slowed tumor growth and prolonged survival in p50(f/f);Lys-Cre mice may in part reflect poor p50 exon 4 deletion in microglia. Microglial deletion of exon 4 was evaluated by analysis of RNA in brain CD11b + cells from tumor-free mice, and also in sorted CD11b int CD45 int cells from tumor-bearing mice, in comparison to CD11b hi CD45 hi TIMs (Fig. 6e) . p50 RNA was decreased 80% in TIMs, only 20% in naïve microglia, and 50% in tumor-associated microglia, the latter potentially an underestimate due to inclusion of non-tumor microglia.
Discussion
GL261 gliomas grew substantially slower in p50 −/− compared with WT hosts. Tumor regression was evident after day 14 in 30% of p50 −/− recipients, suggesting effective immune surveillance resulting in prolonged survival. Of note, GL261 cells carry a high mutational burden and express > 1700 neoepitopes [34] .
Gliomas in WT and p50 −/− mice contained a large population of CD45 hi CD11b hi cells. Both TAMs and MDSC have been identified in tumors and support tumor growth. MDSC are immature myeloid cells that can be either granulocytic (Ly6G hi ) or monocytic (Ly6C hi ), both of which are Fig. 1 and were inoculated concurrently with those exposed to the T-cell-depleting Abs. c WT and p50 −/− mice received both CD4 and CD8 antibody (Ab), or no Ab, on days -7, -5, and -3, followed by GL261-Luc cell inoculation on d0 and an additional CD4/CD8 Ab injection on d8. CD11b + cells isolated on day 14 were subjected to qRT-PCR analysis for indicated mRNAs (mean and SE from three determinations) ◂ characterized by low or absent F4/80 and MHCII [7, 35] . We found that the majority of CD45 hi CD11b hi cells were F4/80 hi TAMs in both WT and p50 −/− mice, and only a small proportion expressed Ly6G. Although we observed a large proportion of p50 −/− TIMs expressing intermediate Ly6C, these cells co-expressed high levels of both F4/80 and Fig. 6 Glioma growth is not slowed in mice lacking myeloid NF-κB p50. a PCR analysis of genomic DNA from p50(f/f) and p50(f/f);LysCre mice (left). RNA isolated from BMDM under basal conditions in CSF1 or after stimulation for 24 h with IL-4 (M2 inducer) or IFNγ (M1 inducer) was analyzed by qRT-PCR using p50 exon 4 and exon 6 primers (center, mean and SE from three determinations); total cellular proteins from the same cultures were analyzed by Western blotting for p50 and β-actin (right). b Peritoneal macrophages from p50(f/f) and p50(f/f);Lys-Cre mice were analyzed for p50 RNA by exon 4-6 qRT-PCR (mean and SE from three determinations). c Survival curves of p50(f/f) vs p50(f/f);Lys-Cre mice inoculated on day 0 with GL261-Luc cells, with total number of mice in each group and Log
Rank p values shown (left). Relative IVIS bioluminescence of tumors on days 7, 15, and 21 from the same mice used for survival analysis (right). d RNAs prepared from tumor CD11b + cells on day 14 after GL261-Luc inoculation were subjected to qRT-PCR analysis for indicated M1 and M2 markers. The relative expression of each mRNA, normalized to cyclophilin A, is shown, with expression in p50(f/f) mice set to 1.0. Mean and SE are shown for three mice per group. e p50 RNA expressed was evaluated by exon 4-6 qRT-PCR in microglia (MG) from tumor-free mice and in MG and TIMs sorted from tumors 14 days after GL261 inoculation (mean and SE from three determinations) MHCII, ruling out the possibility that they are suppressive monocytic MDSC. Thus, the glioma-infiltrating myeloid cells in this model are predominantly TAMs and microglia.
When normalized to tumor bioluminescence, we found a threefold increase in TIM density in p50 −/− mice. [32] . Supporting the idea that myeloid NF-κB activation in the absence of p50 contributes to glioma control, inhibition of myeloid-specific PI3Kγ induces TAMs to adopt an M1 phenotype, with increased NF-κB p65 activity and slowed growth of several murine carcinoma lines [36] .
Potentially as a consequence of the observed changes in tumor myeloid cells, we discovered a marked increase in total and IFNγ-expressing CD4 TIL in p50 −/− mice, which outnumbered total and activated CD8 TIL threefold in absolute number, and 10-fold in density. Stimulation with PMA/ionomycin increased IFNγ expression in a greater proportion of CD4 TIL from p50 −/− mice than WT mice. Upon stimulation for 3 days ex vivo using CD3/ CD28 antibodies, we detected increased Granzyme B in CD8 TIL, and increased Granzyme B, IFNγ, and TNFα in CD4 TIL from p50 −/− hosts. We detected no change in Tgfb mRNA expression in p50 −/− CD11b + cells, which correlates with unaltered total numbers of tumor Tregs. However, when increased numbers of IFNγ + CD4 T cells are taken into account, we find a 10-fold decrease in the ratio of Treg:CD4 effectors in tumors from p50 −/− mice. We find a similar trend, albeit a lower twofold change, in the Treg:CD8 effector ratio. Collectively, our T-cell data suggest a greater relevance of CD4 T-cell activation than CD8 T-cell activation for reducing GL261 glioma growth and prolonging survival in the absence of p50. The crucial role of CD4 T cells in controlling brain tumor growth has been seen in the GL261 model upon immune checkpoint blockade and in a medulloblastoma model upon tumor Cdk5 kinase loss that results in reduced tumor PD-L1 [37, 38] . In the clinical setting, low CD4 counts have been correlated with increased tumor growth and earlier death in glioma patients [39, 40] .
The contribution of CD4 and CD8 T cells to slowed tumor growth in p50 −/− hosts was evident from the complete ablation of survival advantage upon CD4 T-cell depletion, and from partial ablation of survival advantage upon CD8 T-cell depletion. CD8 T-cell activation was at least in part cell-intrinsic, as cultured naïve splenic p50 −/− CD8 T cells gave rise to increase Tc1 cells. Although ex vivo naïve splenic p50 −/− CD4 T-cell skewing to Th1, Th2, Th17, or Treg phenotypes was equivalent to that of WT cells, we cannot rule out a cell-intrinsic effect of p50 deletion on tumor CD4 Th1 activation in vivo.
Two additional findings support a role for T-cell-intrinsic changes in the absence of p50 contributing to slowed glioma growth in p50 −/− mice. First, combined CD4 and CD8 T-cell ablation largely reversed tumor myeloid M2 polarization in WT hosts without affecting tumor myeloid M1 polarization in p50 −/− hosts. To our knowledge, these data reveal a largely unappreciated role for T cells in maintaining tumor-supportive TAM M2 polarization. The M1 markers IL-1 and Nos2 were not increased in WT hosts upon T-cell depletion, suggesting that their increase in p50 −/− tumor myeloid cells may result from a myeloid cellintrinsic change. Second, glioma growth was not slowed in p50(f/f);Lys-Cre compared with p50(f/f) tumor recipients. Future experiments will utilize additional Cre transgenes, e.g., CD4-Cre, CD8α-Cre, CD11c-Cre, or combinations, to further dissect the relevant cell types.
Collectively, our findings suggest that targeting NF-κB p50 in both tumor T cells and myeloid cells has the potential to contribute to glioma therapy. Although targeting the p50 protein may be problematic, using a p50 siRNA directed to these cells in vivo represents a viable therapeutic option. Depleting p50 in T cells may both obviate their ability to induce tumor myeloid M2 polarization and directly favor their activation by tumor antigens, whereas depleting myeloid p50 may directly enable their adoption of an anti-tumor M1 phenotype. Importantly, inactivation of the NF-κB p50 transcription factor could potentially avoid resistance mechanisms that arise when upstream, cytoplasmic signaling pathways are targeted.
